Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m². Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.

Evidence-based guidelines for cancer prevention urge avoiding behaviors that can lead to obesity, including overconsumption of energy-dense foods and beverages and a sedentary lifestyle. Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m². Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.

**Abstract**

Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m². Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.

**Keywords:** Obesity; Diabetes; Cancer; Metformin.
are breast [16], bladder [17, 18], kidney [19], and colorectal cancer [20]. No association has been identified between diabetes and prostate cancer [21, 22]. It is still not understood why diabetes associates with increased risk of developing some but not all types of cancers, and further investigation is needed regarding this issue.

Herein, we discuss possible mechanisms underlying the links between obesity, T2D and cancer, with emphasis on obesity-associated enhancements in growth factor signaling, inflammation, and angiogenic processes and on the crosstalk between macrophages, adipocytes, endothelial cells and epithelial cells in many cancers.

**Dysregulated Growth Signals**

**Insulin and IGF-I**

Insulin is a peptide hormone produced by pancreatic beta cells and released in response to elevated blood glucose. Hyperglycemia, a hallmark of metabolic syndrome, is associated with insulin resistance, aberrant glucose metabolism, chronic inflammation, and the production of other metabolic hormones such as IGF-I, leptin and adiponectin [23]. Sharing ~50% sequence homology with insulin, IGF-I is a peptide growth factor produced primarily by the liver following stimulation by growth hormone. IGF-I regulates growth and development of many tissues, particularly prenatally [24]. IGF-I in circulation is typically bound to IGF binding proteins (IGFBPs) that regulate the amount of free IGF-I bioavailable to bind to the IGF-I receptor (IGF-IR) and elicit growth or survival signaling [24]. In metabolic syndrome, the amount of bioavailable IGF-I increases, possibly via hyperglycemia-induced suppression of IGFBP synthesis and/or hyperinsulinemia-induced promotion of hepatic growth hormone receptor expression and IGF-I synthesis [23]. Elevated circulating IGF-I is an established risk factor for many cancer types [25].

In many tumors, binding of IGF-I and IGF-II to the IGF-IR inhibits apoptosis and promotes cell proliferation. IGF-I can also bind and form heterodimers with insulin receptors subtypes A and B (IR-A and IR-B), generating hybrids. IR-A has high affinity for insulin and IGF-II but binds IGF-I with low affinity. IR-A binds insulin with 1.5-fold higher affinity than IR-B, possesses a higher dissociation and internalization rate, and mimics many of the cell signaling and cell survival activities of IGF-IR (described below). In contrast, IR-B is thought to mediate most of the classic metabolic responses induced by insulin, and also binds IGF-I and IGF-II with low and intermediate affinity, respectively [26]. Both IGFs- and insulin-mediated induction of cell proliferation and migration is more effective in cells containing IGF-IR/IR-A hybrids than in cells containing IGF-IR/IR-B hybrids [27]. Interestingly, an increase in the IR-A to IR-B ratio has been reported in Type 2 diabetes [28, 29]. Activation of the IR-A by insulin-like IGF-II bypasses the IGF-IR and its inhibition may explain the reason of the failure of monotherapy trials with IGF-IR targeted antibody or with IGF-IR specific tyrosine kinase inhibitors [30].

**Signaling Pathways Downstream of the Insulin Receptor and IGF-1R**

Downstream targets of IR-A and IGF-IR comprise a signaling network regulating cellular growth and survival predominately through induction of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway [24]. This signaling cascade, elegantly reviewed by Cantley and colleagues [31], is one of the most commonly altered pathways in human epithelial tumors. Engagement of the PI3K/Akt pathway allows both intracellular and environmental cues, such as energy availability and growth factor supply, to affect cell growth, proliferation, survival and metabolism. Activation of the insulin receptor or IGF-IR stimulates PI3K to produce the lipid second messenger, phosphatidyl-inositol-3,4,5-trisphosphate. This messenger recruits and anchors Akt to the cell membrane for further phosphorylation and activation. Akt is a cAMP-dependent, cGMP-dependent protein kinase C that when constitutively active is sufficient for cellular transformation by stimulating cell cycle progression and cell survival and by inhibiting apoptosis. Frequently associated with the aberrant Akt signaling commonly seen in human cancers is an increase in mTOR (mammalian target of rapamycin) signaling [32]. mTOR is a serine/threonine protein kinase that is activated by Akt and inhibited by an opposing signal from AMP-activated kinase (AMPK). At the interface of the Akt and AMPK pathways, mTOR dictates translational control of new proteins in response to both growth factor signals and nutrient availability through phosphorylation of its downstream mediators [33, 34]. Ultimately, activation of mTOR results in cell growth, cell proliferation, and resistance to apoptosis. Additionally, elevated cellular amino acids (particularly branched chain amino acids), glucose, and ATP concentrations, which occur during high-energy conditions, signal for mTOR activation [34].

**Leptin, Adiponectin and their Ratio**

Leptin is a peptide hormone produced by adipocytes, is positively correlated with adipose stores and nutritional status, and functions as an energy sensor to signal the brain to reduce appetite. In the obese state, adipose tissue overproduces leptin, and the brain no longer responds to the signal. Insulin, glucocorticoids, tumor necrosis factor-alpha (TNF-α), and estrogens all stimulate leptin release [35, 36]. Leptin has direct effects on peripheral tissues, indirect effects on hypothalamic pathways and modulates immune function, cytokine production, angiogenesis, carcinogenesis and other biological processes [36]. The leptin receptor has similar homology to class I cytokines that signal through the janus kinase and signal transducer activator of transcription (JAK/STAT) pathway that is often dysregulated in cancer [36].

Adiponectin is a hormone mainly secreted from visceral adipose tissue. Levels of adiponectin, in contrast with leptin, negatively correlate with adiposity. Adiponectin functions to counter the metabolic program associated with obesity and hyperleptinemia by modulating glucose metabolism, increasing fatty acid oxidation and insulin sensitivity, and decreasing production of inflammatory cytokines [37]. The possible mechanisms through which adiponectin exerts anticancer effects may include increasing insulin sensitivity, and decreasing insulin/IGF-I and mTOR signaling via activation of AMPK. Adiponectin also reduces (and leptin increases) proinflammatory cytokine expression via modulation of JAK/STAT pathway and the the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) [38-40]. Although *in vitro*, animal and epidemiologic evidence linking leptin [41-44] or adiponectin [39-45] individually to cancer risk is mixed, data suggest that the adiponectin/leptin ratio is a useful atherogenic and metabolic syndrome index, particularly in Type 2 diabetes, and is also associated with cancer risk [45]. However, further characterization of these links is needed.

**Special Issue on “Emerging Focus in Diabetes Research”**

**Cytokines and Crosstalk Between Adipocytes, Macrophages and Epithelial Cells**

Obesity and metabolic syndrome are associated with a low-grade, chronic state of inflammation characterized by increased circulating free fatty acids and chemotraction of immune cells (such as macrophages that also produce inflammatory mediators) into the local milieu [46-48]. These effects are further amplified by the release of inflammatory cytokines such as interleukin (IL)-1β, IL-6, TNF α and monocyte chemoattractant protein (MCP)-1. Adipocytes can enlarge past the point of effective oxygen exchanges, which results in hypoxia and eventually necrosis. Free fatty acids escape the engorged/necrotic adipocytes and deposit in other tissues, which in turn promotes insulin resistance and diabetes (through downregulation of insulin receptors and glucose transporters), hypertension, and fatty liver disease and also activates signaling molecules involved in epithelial carcinogenesis, such as NF-kB [49, 50].

NF-kB is a transcription factor that is activated in response to bacterial and viral stimuli, growth factors, and inflammatory molecules (eg, TNF-α, IL-6, and IL-1β), and is responsible for inducing gene expression associated with cell proliferation, apoptosis, inflammation, metastasis, and angiogenesis. Activation of NF-kB is a common characteristic of many tumors and is associated with insulin resistance and elevated circulating levels of leptin, insulin, and/or IGF-1 [49, 50].

**Inflammation and Cancer**

The link between chronic inflammation and cancer development was first noticed more than 100 years ago by Rudolph Virchow when he observed an abundance of leukocytes in neoplastic tissue [51]. Now, several tissue-specific inflammatory lesions are established neoplastic precursors for invasive cancer, including gastritis for gastric cancer, inflammatory bowel disease for colon cancer, and pancreatitis for pancreatic cancer [52, 53].

Tumor microenvironments are composed of multiple cell types including epithelial cells, fibroblasts, mast cells, and cells of the innate and adaptive immune system [53, 54]. As discussed previously, macrophages, which are activated in the obese state, infiltrate tumors and amplify the inflammatory tumor microenvironment through production of cytokines, prostaglandins, and angiogenic factors [53]. Another important cancer-related inflammatory mediator is cyclooxygenase (COX)-2, an enzyme that is upregulated in most tumors and catalyzes the synthesis of the potent inflammatory lipid metabolite, prostaglandin E₂. The overexpression is an indicator of poor prognosis in multiple cancer types [55].

**Vascular Integrity-Related Factors**

**Plasminogen Activator Inhibitor-1 (PAI-1)**

PAI-1 is a serine protease inhibitor produced by endothelial cells, stromal cells and adipocytes in visceral white adipose tissue [62]. Increased circulating PAI-1 levels, frequently found in obese subjects, are associated with increased risk of atherogenesis and cardiovascular disease, diabetes and several cancers [4, 56]. PAI-1, through its inhibition of urokinase-type and tissue-type plasminogen activators, regulates fibrinolysis and integrity of the extracellular matrix. PAI-1 is also involved in angiogenesis and thus may contribute to obesity-driven tumor cell growth, invasion and metastasis [4].

**Vascular Endothelial Growth Factor (VEGF)**

VEGF, a heparin-binding glycoprotein produced by adipocytes and tumor cells, has angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells [57]. Circulating levels of VEGF are increased in obese, relative to lean, humans and animals, and increased tumoral expression of VEGF is associated with poor prognosis in several obesity-related cancers [58]. The need for nutrients and oxygen triggers tumor cells to produce VEGF, which leads to the formation of new blood vessels to nourish the rapidly growing tumor and facilitate the metastatic spread of tumors cells [57]. Adipocytes communicate with endothelial cells by producing a variety of proangiogenic and vascular permeability-enhancing factors. These include VEGF, IGF-1, PAI-1, leptin, hepatocyte growth factor, and fibroblast growth factor-2 [59]. In the obese, non-tumor setting, these factors stimulate neovascularization in support of the expanding fat mass. These adipose-derived factors may also contribute to obesity-associated enhancement of tumor angiogenesis. However, the relative contributions of tumor-derived, versus adipocyte-derived, proangiogenic factors in tumor development, progression and metastasis remain unclear.

**Tumor angiogenesis**

Adipocytes communicate with endothelial cells by producing a variety of proangiogenic and vascular permeability-enhancing factors, including vascular endothelial growth factor (VEGF), IGF-1, plasminogen activator inhibitor (PAI)-1, leptin, hepatocyte growth factor, and fibroblast growth factor-2 [59]. In the obese state, these factors stimulate neovascularization in support of the expanding fat mass. Insulin resistance also drives abnormalities in endothelial and vascular smooth muscle function via alterations in many of the same proangiogenic and vascular altering factors [59]. These factors may also contribute to obesity-associated enhancement of tumor angiogenesis. For example, VEGF is a heparin-binding glycoprotein produced by adipocytes and tumor cells that has angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells [57]. Circulating levels of VEGF are increased in obese, relative to lean, humans and animals, and increased tumoral expression of VEGF is associated with poor prognosis in several obesity-related cancers [58]. The need for nutrients and oxygen triggers tumor cells to produce VEGF, which leads to the formation of new blood vessels to nourish the rapidly growing tumor and facilitate the metastatic spread of tumors cells [57]. Bevacizumab-based therapy (i.e., anti-VEGF therapy), in combination with conventional chemother-apy, is considered a first-line treatment option for patients with advanced colorectal cancer; however, decreased efficacy in obese patients is reported and speculated to be associated with increased levels of VEGF (and/or other proangiogenic factors) produced by visceral white adipose tissue [60, 61]. The relative contributions of tumor-derived, versus adipocyte-derived, proangiogenic factors in tumor development, progression and metastasis remain unclear. PAI-1 is a serine protease inhibitor produced by endothelial cells, stromal cells and adipocytes in visceral white adipose tissue [56]. Increased circulating PAI-1 levels, frequently found in
obese subjects, are associated with increased risk of atherogenesis and cardiovascular disease, diabetes and several cancers [56, 4]. PAI-1, through its inhibition of urokinase-type and tissue-type plasminogen activators, regulates fibrinolysis and integrity of the extracellular matrix. PAI-1 is also involved in angiogenesis and thus may contribute to obesity-driven tumor cell growth, invasion and metastasis [4].

**Cancer and Diabetes: Role of Antioxidant**

T2D shares multiple risk factors with several cancers, such as obesity, hyperinsulinemia and hyperglycemia. The cancer-obesity association has been known for many years [62, 63], and could be explained by the fact that central obesity often leads to chronic levels of inflammation and oxidative stress [64], which are risk factors for the development of many cancers. Excess body weight and adiposity associates with reduced insulin sensitivity, which is compensated by increased insulin secretion, to avoid an increase in blood glucose level [65]. Obesity-related hyperinsulinemia regulates the secretion of adipokines by adipocytes that together with macrophages infiltrating the adipose tissue, secrete a number of pro-inflammatory cytokines as tumor necrosis factor (TNF-α) and interleukin-(IL)-6. The induced systemic inflammatory response worsens insulin resistance [66], contributing to increase the risk of pancreatic cancer through insulin/IGF-1 signaling cascades.

Obesity-induced reactive oxygen species (ROS) production represents an additional risk factor for the development of pancreatic cancer in T2D patients. Hyperglycemia increases oxidative stress and up-regulate the oxidative machinery. Specifically, hyperglycemia activates the polyol pathway through increased expression and activity of aldose reductase. It has been hypothesized that the hyperglycemia-induced activation of polyol metabolism may explain the decreased pancreatic secretion observed in insulin-dependent diabetes mellitus patients [67, 68]. In *vivo*, glucose-induced activation of sorbitol accumulation and nuclear factor-κB (NFκB) activation can be prevented by normalizing levels of mitochondrial ROS [69]. Additional studies have also reported lower levels of other cellular antioxidants, namely copper/zinc superoxide dismutase, catalase, and glutathione peroxidase (GPx), in human pancreatic cancer specimens compared with normal pancreatic specimens [67, 70]. Although these mechanisms still need to be more clarified, these findings suggest that cellular antioxidants play a crucial role in regulating pancreatic tumor growth.

**Cancer and Antidiabetic Drugs**

**Metformin**

Metformin (1,1-dimethylbiguanide hydrochloride) is a member of the biguanide class of oral agents developed for the treatment of hyperglycemia and T2D. Discovered more than 50 years ago, metformin still represents the most commonly prescribed drug for T2D patients as initial or combined therapy [71]. Epidemiologic studies suggest that metformin use is associated with reduced risk among diabetics of being either diagnosed with, or dying from several cancers, particularly pancreatic cancer (PC) [72]. However, the causal relationship and potential mechanisms underlying the association between metformin and reduced PC have not been established.

With regard to diabetes, metformin decreases hyperglycemia by inhibiting hepatic gluconeogenesis and increasing glucose uptake in the peripheral tissues, as skeletal muscles and adipose tissue, ultimately improving insulin sensitivity [73]. These effects are achieved by activation of AMPK a sensor of the cellular metabolic state [74, 75]. Metformin-induced AMPK negatively regulates mTOR pathway, which is involved in protein synthesis and cell proliferation. With respect of cancer, metformin might directly achieve inhibition of tumor cell growth through induction of AMPK. Indirectly, metformin affects tumor growth in T2D patients by decreasing insulin, a promoting-growth hormone, with mitogenic effects. It has been proposed that hyperinsulinemia together with insulin resistance might promote carcinogenesis [76] since several *in vivo* studies have shown that antitumour effect of metformin is more effective in mice on high-energy diet associated with hyperinsulinemia than those on control diet [77]. Metformin has been shown to inhibit cell proliferation, colony formation and partial cell cycle arrest [78-80] in several cancer cell lines. In addition to the above mechanisms, metformin may also exert its anti-tumor effect through regulation of microRNA (miRNAs), noncoding RNA molecules that post-transcriptionally regulate gene expression [81]. MiRs regulate cellular processes involved in cancer initiation, recurrence, and metastasis [82]. Our recent study conducted in a murine pancreatic cancer transplant model in obese/prediabetic mice found that metformin induced tumoral expression of miRNA-34a [83], a miR typically lost during cancer progression, including pancreatic tumors [84, 85]. MiR-34a has been shown to contribute to reduce survivability in those diagnosed with pancreatic cancer [86]. MicroRNA-34a suppresses key events of the epithelial-to-mesenchymal transition (EMT) by acting as a negative regulator of the signaling pathway activated by transforming growth factor-β (TGF-β), a master regulator of EMT [87]. Expression of EMT mediators, such as Snail is profoundly linked to TGF-β signaling and miR-34a expression. Specifically, as TGF-β increases, expression of miR-34a is diminished and Snail is enhance [88], while re-expression of miR-34a reduces expression of Snail and other EMT mediators such as Notch and Slug [89]. Metformin modulates EMT-related targets, such as Notch, in a miR-34a-dependent manner [90]. Dysregulation of Notch signaling, a targeted perturbation in many cancer types has been shown to enhance hypoxia-induced tumor cell migration and invasion and influence expression of Snail and Slug [91].

**Rosiglitazone**

Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The thiazolidinediones are agonists for peroxisome-proliferator–activated receptor γ (PPAR-γ). PPAR-γ receptors are ligand-activated nuclear transcription factors that modulate gene expression, lowering blood glucose primarily by increasing insulin sensitivity in peripheral tissues [92]. However, despite clear benefits in glycemic control, this class of drugs has recently fallen into disuse due to concerns over side effects and adverse events as extensively discussed by Socioc and colleagues in a recent review [93]. Results of available epidemiological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal [94]. Evidence of both pro-carcinogenic and anti-tumorogenic effects of PPARγ agonists have been mainly reported *in vitro* and *in vivo* models that do not take into full account the metabolic characteristics of patients with diabetes. A population-based report published by Govindarajan and colleagues [95] showed that T2D associates with reduced risk of lung cancer in diabetic patients in agreement with previous in

vitro studies [96]. Ramos-Nino and colleagues showed an association between the use of TZDs and cancer in a community-based population of adults with diabetes participating in the Vermont Diabetes Information System (VDIS) [97]. The association was observed primarily among rosiglitazone users and not among subjects using pioglitazone. Furthermore, the association was found in women, but not in men. A case-control study published in 2013 showed that long-term exposure to rosiglitazone, or pioglitazone, increases the risk of bladder cancer in T2D patients [98].

**Conclusion**

Multiple hormones, growth factors, cytokines and other mediators associated with the obese state and the metabolic syndrome enable crosstalk between macrophages, adipocytes, endothelial cells and epithelial cells and contribute to cancer-related processes (including growth signaling, inflammation and vascular alterations) (Figure 1). Components of these interrelated pathways represent promising mechanism-based targets for the resolution of diabetes-induced cancer. Moreover, compounds that are beneficial for diabetes and cancer such as metformin represent a promising intervention that should be tested in future translational studies evaluating new strategies for breaking the diabetes-cancer link.

**Acknowledgments**

Dr. S. Hursting is funded, in part, by grants from the National Cancer Institute (R01CA129409), the Breast Cancer Research Foundation (UTA09-001068), and the National Institute of Environmental Health Sciences (P30ES007784). The authors have nothing to disclose.

**References**


[12]. Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic...


[15]. El-Serag HB, Hampel H, Javadi F (2006) The association between diabe-


[18]. Larsson SC, Wolk A (2007) Diabetes mellitus and incidence of kidney can-


[20]. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorec-


[23]. Braun S, Bitton-Worms K, LeRoith D (2011) The link between the meta-

[24]. Pollak M (2008) Insulin and insulin-like growth factor signalling in neo-

e and carcinogenesis: lessons learned from 30 years of calorie restric-

[26]. Chao W, D’Amore PA (2008) Igf2: epigenetic regulation and role in devel-


[31]. Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling r

[32]. Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, et al. (1998) Spontaneous in-

[33]. Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin re-


[35]. Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysi-

[36]. Renehan AG (2010) Body fatness and bevacizumab-based therapy in met-


[40]. Renehan AG (2010) Body fatness and bevacizumab-based therapy in met-


[50]. Cullen JJ, Mitros PA, Oberley LW (2005) Expression of antioxidant en-


